AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05052723
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Trial: NCT06576882
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Participants will receive Vonoprazan 20 mg tablets twice daily before meals.
Trial: NCT06576882
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].
Trial: NCT05270733
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
Trial: NCT05511909
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Trial: NCT05511909
Drug: Lofexidine
RxNorm normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Trial: NCT05904093
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).
Trial: NCT05075993
Drug: LVGN3616 + LVGN6051 + Nab-Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV, Given by PO
Trial: NCT05075993
Drug: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV, Given by PO
Trial: NCT05075993
Drug: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV, Given by PO
Trial: NCT05075993
Drug: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV, Given by PO
Trial: NCT05773326
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
Trial: NCT05441813
Drug: Virgin Coconut Oil
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
DrugBank: Coconut (DB10523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care with the addition of virgin coconut oil mouth rinse
Trial: NCT05027802
Drug: Palovarotene
RxNorm normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene will be taken orally once daily at approximately the same time each day.
Trial: NCT03810287
Drug: Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.
Trial: NCT05850546
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
Trial: NCT06082063
Drug: Aspirin tablet
RxNorm normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
Trial: NCT06082063
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
Trial: NCT06082063
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.
Trial: NCT06082063
Drug: Finerenone
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.
Trial: NCT04976660
Drug: TT-4
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
Trial: NCT04675710
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04675710
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05215340
Drug: Datopotamab Deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Trial: NCT05215340
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Trial: NCT05065970
Drug: Felzartamab
RxNorm normalized name: Felzartamab
DrugBank: Felzartamab (DB16375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD38+ monoclonal antibody
Trial: NCT05591144
Drug: Prednisone tablet
RxNorm normalized name: Prednisone Tablets
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose selection of oral prednisone is the maximum daily dose based on weight for 4 days, followed by a taper every 2 days, with the maximum duration to 14 days.
Trial: NCT05591144
Drug: Ginkgo Biloba Extract
RxNorm normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
Trial: NCT05553366
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT05402865
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab, subcutaneous injection, specific usage to see the medical records. Non-denosumab, specific usage to see the medical records.
Trial: NCT06267170
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with adbelizumab
Trial: NCT05145127
Drug: PF-06741086
RxNorm normalized name: Immunoglobulin g1, anti-(human tissue factor pathway inhibitor) (human monoclonal pf-06741086 .gamma.1-chain), disulfide with human monoclonal pf-06741086 .lambda.-chain, dimer
DrugBank: Marstacimab (DB17725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria.
Trial: NCT05030155
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg/month subcutaneous
Trial: NCT05807347
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L
Trial: NCT04719273
Drug: Extended-release Onapristone
RxNorm normalized name: Onapristone
DrugBank: Onapristone (DB12637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04719273
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06514209
Drug: cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
Trial: NCT05142696
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
Trial: NCT05167409
Drug: Evorpacept (ALX148)
RxNorm normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV QW
Trial: NCT05167409
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV QW
Trial: NCT05167409
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Q3W
Trial: NCT04685941
Drug: Drug-mediated hyperemia
RxNorm normalized name: carbinoxamine maleate Oral Solution [Pediatex]
DrugBank: Carbinoxamine (DB00748)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
Trial: NCT05691699
Drug: ABBV-903
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule; oral
Trial: NCT05691699
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule; oral
Trial: NCT05011266
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
Trial: NCT05308446
Drug: Encorafenib
RxNorm normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06539806
Drug: Losartan 50mg Tab
RxNorm normalized name: LOSARTAN 50MG TAB
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
Trial: NCT05279690
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
Trial: NCT04675060
Drug: TQ-B3139 capsules
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
Trial: NCT04516967
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral avatrombopag tablet or sprinkle capsule
Trial: NCT03773770
Drug: Triheptanoin
RxNorm normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid for oral (PO) or enteral tube administration
Trial: NCT05461807
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
Trial: NCT05461807
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
Trial: NCT06315608
Drug: MRG-001
RxNorm normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRG-001 is a clear liquid solution for subcutaneous injection
Trial: NCT06053749
Drug: Avonex (IFNβ-1-a, Biogen Netherlands B.V)
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Trial: NCT06053749
Drug: Rebif (IFNβ-1-a, Merck Europe B.V.)
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Trial: NCT06053749
Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited)
RxNorm normalized name: Extavia
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Trial: NCT06053749
Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)
RxNorm normalized name: IFNγ
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Trial: NCT06053749
Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)
RxNorm normalized name: Plegridy
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Trial: NCT06053749
Drug: MS disease modifying drugs (MSDMDs)
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Trial: NCT06027554
Drug: Mitoquinone Mesylate
RxNorm normalized name: mesylate
DrugBank: Mitoquinone (DB05063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ given 20 mg per day for 12 weeks.
Trial: NCT05334810
Drug: DP303c
RxNorm normalized name: ADC DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP303c injection, 3.0 mg/kg, every 3 weeks.
Trial: NCT06004336
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT05774951
Drug: Camizestrant
RxNorm normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camizestrant. Experimental. Administered orally
Trial: NCT05774951
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen. Comparator. Administered per local approved label
Trial: NCT05774951
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole. Comparator. Administered per local approved label
Trial: NCT05774951
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole. Comparator. Administered per local approved label
Trial: NCT05774951
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane. Comparator. Administered per local approved label
Trial: NCT06001788
Drug: Ziftomenib
RxNorm normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06001788
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06001788
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06001788
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT06001788
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration
Trial: NCT06425198
Drug: BMS-986278
RxNorm normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06310473
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg intravenous (IV) every 3 weeks ;
Trial: NCT06310473
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m², iv drip for 2h, d1, q3w;
Trial: NCT05371054
Drug: venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered orally, days 1-10, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
Trial: NCT05993182
Drug: Ephedrine 5mg
RxNorm normalized name: CARBETAPENTANE 30MG/CTM 4MG/EPHEDRINE 5MG/P-EPHRINE 5MG/5ML SUSP
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
Trial: NCT05993182
Drug: Ephedrine 10mg
RxNorm normalized name: CHLORPHENIRAMINE 0.67MG/PSEUDOEPHEDRINE 10MG/5ML LIQUID
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
Trial: NCT05993182
Drug: Ephedrine 15mg
RxNorm normalized name: APAP 325/PSEUDOEPHEDRINE 15MG TAB
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
Trial: NCT05371054
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
Trial: NCT06570655
Drug: Huperzine A injection
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular
Trial: NCT06570655
Drug: Huperzine A injection
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous bolus
Trial: NCT06025396
Drug: TMP-301
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose active